Last Updated: 19 Sep 2024
Executive Summary
Voyager Therapeutics Inc. (VYGR) is a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases. The company's market capitalization is $339.74 million, and its latest stock price is $6.23. VYGR has a trailing P/E ratio of 23.07 and an analyst target price of $17.63.
Company Overview
Voyager Therapeutics was founded in 2014 and is headquartered in Cambridge, Massachusetts. The company's lead product candidate is VY-HTT01, a gene therapy for the treatment of Huntington's disease. VY-HTT01 is currently in Phase 3 clinical trials. Voyager Therapeutics also has a number of other gene therapy programs in development for the treatment of neurological diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
Fundamental Analysis
Voyager Therapeutics reported revenue of $143.77 million for the fiscal year ended December 2023. The company's gross profit was -$19.86 million, and its net loss was $17.84 million. Voyager Therapeutics has a strong balance sheet with $272.7 million in cash and equivalents.
Technical Analysis
VYGR's stock price has been trading in a range between $5.97 and $11.72 over the past 52 weeks. The stock's 50-day moving average is $7.42, and its 200-day moving average is $8.10. VYGR's relative strength index (RSI) is 45.77, which indicates that the stock is neither overbought nor oversold.
Short Term Outlook
VYGR's stock price is currently trading below its 50-day and 200-day moving averages. The stock's RSI is also below 50, which indicates that the stock is in a downtrend. In the short term, VYGR's stock price is likely to continue to trade in a range between $5.97 and $7.42.
Long Term Outlook
VYGR's long-term outlook is positive. The company has a strong pipeline of gene therapy programs, and its lead product candidate, VY-HTT01, is currently in Phase 3 clinical trials. If VY-HTT01 is successful in clinical trials, it could be a major commercial success for Voyager Therapeutics.
Analyst Recommendations
The majority of analysts have a buy rating on VYGR. The average analyst target price is $17.63, which represents a potential upside of 182.6% from the current stock price.
Disclaimer
The information contained in this report is for informational purposes only and should not be construed as investment advice. Investors should always conduct their own due diligence before making any investment decisions.
